Juvenescence
VC Fund
Douglas, Isle of Man
Juvenescence is a VC fund in Douglas focused on Biotechnology and Pharmaceutical. Juvenescence Limited is a British Virgin Islands-based holding company that invests in human aging and longevity. Juvenescence has raised $111M to build an ecosystem and pipeline of assets targeting aging, age-related disease, and regeneration. Juvenescence believes that recent scientific and medical advances will enable the development oftherapeutics that meaningfully extend human healthspan and eventually lifespan. A meaningful increase in lifespan in the already aging world will have profound implications on all sectors of society, and in particular healthcare, education, insurance, and leisure.The company creates and partners with new companies with longevity-related therapeutics, by in-licensing compounds from academia and industry, or forming joint ventures with the foremost longevity scientists and leading research institutions. Their work is based on a novel scientific understanding of the underlying biological causes of aging, to create evidence-based therapeutics that can treat diseases of aging.Juvenescence's goal is to extend both lifespan and healthspan, by developing therapeutics that slow aging and promote juvenescence.
- Total investments:
- 17
- Last investment:
- Lead investor:
- 47%
Last updated:
For AI agents: llms.txt
Industries Juvenescence invests in
Stages Juvenescence invests in
Countries Juvenescence invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 11 contacts → | |||
Round size
- Series A
- $3M–$19M
- Venture - Series Unknown
- $1.5M–$10M
Investment Focus
Industry
- Biotechnology 9 (53%)
- Pharmaceutical 4 (24%)
- Health Care 3 (18%)
- Medical 2 (12%)
- Life Science 2 (12%)
Stage
- Venture - Series Unknown 5 (29%)
- Series A 3 (18%)
- Seed 1 (6%)
- Debt Financing 1 (6%)
- Private Equity 1 (6%)
Country
- United States 8 (47%)
- Hong Kong 1 (6%)
- Isle of Man 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Anthony Chow
VP IR
|
VP IR | Total investments: 0 | Find email | |
Jim Mellon
Chairman
|
Chairman | Total investments: 35 | Find email | |
Alexander Pickett
Managing Director
|
Managing Director | Total investments: 1 | Find email | |
Casey Swerner
Vice President
|
Vice President | Total investments: 0 | Find email | |
Declan Doogan
Chief Medical Officer
|
Chief Medical Officer | Total investments: 3 | Find email | |
| See all 11 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| LyGenesis is an organ regeneration company enabling a patient's own lymph nodes to be used as bioreactors to regrow functioning ectopic organs. Their initial target organ for clinical development is liver regeneration, with a focus on helping patients with end stage liver disease (ESLD). | $19M / Series A / Oct 24, 2023 | ||
| Morphoceuticals is a biotechnology platform establishing a basis for limb regeneration and the discovery of regenerative interventions. It focuses on the understanding of the biophysical mechanisms that implement decision-making during complex pattern regulation and utilizes bioelectric dynamics to change developmental patterning and spurregeneration in organisms that do not regenerate tissues or organs. It helps medical researchers to treat complicated health states through limb regeneration, improving amputation stump health, promoting organ regeneration, and the treatment of channelopathies. | $8M / Seed / Jan 23, 2023 | ||
| MDI Therapeutics is an operator of a discovery stage company focused on developing novel therapies for fibrotic diseases. The company have developed a proprietary discovery platform which has successfully identified novel small molecule and protein drug candidates, and have advanced these programs through key translational experiments usingclinical biomarkers. | $9M / Series A / Mar 02, 2022 | ||
| LyGenesis is an organ regeneration company enabling a patient's own lymph nodes to be used as bioreactors to regrow functioning ectopic organs. Their initial target organ for clinical development is liver regeneration, with a focus on helping patients with end stage liver disease (ESLD). | $11M / Convertible Note / Dec 30, 2020 | ||
| LyGenesis is an organ regeneration company enabling a patient's own lymph nodes to be used as bioreactors to regrow functioning ectopic organs. Their initial target organ for clinical development is liver regeneration, with a focus on helping patients with end stage liver disease (ESLD). | $4M / Debt Financing / Oct 21, 2019 | ||
|
Souvien Therapeutics
|
Souvien Therapeutics is a biotechnology company focused on developing therapeutic agents to modulate critical epigenetic mechanisms associated with neurodegeneration. | $3.5M / Venture - Series Unknown / May 28, 2019 | |
|
BYOMass
|
BYOMass is developing therapeutics to modulate the central control of metabolism associated with aging and age-related chronic illnesses. | $1.5M / Venture - Series Unknown / Mar 27, 2019 | |
|
BHB Therapeutics
|
BHB Therapeutics is developing novel approaches to induce a state of ketosis, which may have protective effects against age-related disease. | $3M / Venture - Series Unknown / Feb 04, 2019 | |
| AgeX is a biotechnology company focused on the development of novel therapeutics for age-related degenerative disease. AgeX’s mission is to apply the proprietary technology platform related to telomerase-mediated cell immortality and regenerative biology to address a broad range of diseases of aging. The current preclinical development effortsinclude two cell-based therapies derived from telomerase-positive pluripotent stem cells and two product candidates derived from the company’s proprietary induced Tissue Regeneration (iTR™) technology. AGEX-BAT1 and AGEX-VASC1 are cell-based approaches in the preclinical stage of development comprised of young regenerative cells modified using AgeX’s UniverCyte™ technology facilitating immune tolerance, formulated in HyStem® matrix, designed to correct metabolic imbalances in aging and to restore vascular support in ischemic tissues respectively. AGEX-iTR1547 is a drug-based formulation in preclinical development intended to restore regenerative potential in a wide array of aged tissues afflicted with degenerative disease using the company’s proprietary iTR technology. | $43.2M / Private Equity / Sep 04, 2018 | ||
|
Napa Therapeutics
|
Napa Therapeutics is a biotechnology company focused on a novel target linked to one of the fundamental processes of aging. A privately held British Virgin Islands company with an office in the Isle of Man, Napa is developing small molecule drugs to address this target. | $3M / Venture - Series Unknown / Aug 06, 2018 | |
| See all 17 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Juvenescence invest in?
Juvenescence invests primarily in Biotechnology, Pharmaceutical and Health Care startups, most often at Venture - Series Unknown and Series A stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Juvenescence invest in?
Juvenescence typically joins rounds of $3M–$19M at Series A and $1.5M–$10M at Venture - Series Unknown. These are whole funding-round sizes, not Juvenescence's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Juvenescence took part in.
How do I contact Juvenescence?
Public channels for Juvenescence include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Juvenescence?
The team at Juvenescence includes Anthony Chow (VP IR), Jim Mellon (Chairman) and Alexander Pickett (Managing Director), among 11 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
